Compugen Stock Price, News & Analysis (NASDAQ:CGEN) $0.79 +0.01 (+1.28%) (As of 12/5/2023 ET) Add Compare Share Share Today's Range$0.77▼$0.8350-Day Range$0.53▼$0.9652-Week Range$0.53▼$1.49Volume382,278 shsAverage Volume363,156 shsMarket Capitalization$68.43 millionP/E RatioN/ADividend YieldN/APrice Target$8.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Compugen MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.60 Rating ScoreUpside/Downside954.9% Upside$8.33 Price TargetShort InterestHealthy1.62% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.31) to ($0.44) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.93 out of 5 starsMedical Sector636th out of 948 stocksBiotechnology Industry25th out of 46 stocks 3.3 Analyst's Opinion Consensus RatingCompugen has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 4 buy ratings, no hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $8.33, Compugen has a forecasted upside of 954.9% from its current price of $0.79.Amount of Analyst CoverageCompugen has received no research coverage in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted1.62% of the float of Compugen has been sold short.Short Interest Ratio / Days to CoverCompugen has a short interest ratio ("days to cover") of 7.7.Change versus previous monthShort interest in Compugen has recently decreased by 10.60%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldCompugen does not currently pay a dividend.Dividend GrowthCompugen does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CGEN. Previous Next 2.2 News and Social Media Coverage News SentimentCompugen has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.37 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Compugen this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for CGEN on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Compugen to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Compugen insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.50% of the stock of Compugen is held by insiders.Percentage Held by InstitutionsOnly 13.25% of the stock of Compugen is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Compugen are expected to decrease in the coming year, from ($0.31) to ($0.44) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Compugen is -2.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Compugen is -2.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCompugen has a P/B Ratio of 0.88. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Compugen Stock (NASDAQ:CGEN)Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.Read More CGEN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CGEN Stock News HeadlinesDecember 5, 2023 | finance.yahoo.comIs Compugen (CGEN) Outperforming Other Medical Stocks This Year?November 9, 2023 | finance.yahoo.comWill Compugen (NASDAQ:CGEN) Spend Its Cash Wisely?December 6, 2023 | Financial Alphas (Ad)Countries Are Investing Heavily Into Securing Energy IndependenceThere's a worldwide "arms race" for countries to secure lithium - the critical metal essential to powering the world's green energy transition. While the U.S. is now investing heavily into lithium production, the North American supply chain has fallen far behind. One company is on a mission to change that and make a previously remote area the next great lithium mining hub.November 8, 2023 | finance.yahoo.comCompugen Ltd. (NASDAQ:CGEN) Q3 2023 Earnings Call TranscriptNovember 8, 2023 | msn.comCompugen GAAP EPS of -$0.11 misses by $0.02November 7, 2023 | sfgate.comCompugen: Q3 Earnings SnapshotNovember 6, 2023 | msn.comCompugen Q3 2023 Earnings PreviewNovember 6, 2023 | finance.yahoo.comCompugen's COM701 (anti-PVRIG) Mediates Anti-Tumor Activity in Patients Typically Not Responding to ImmunotherapyDecember 6, 2023 | Financial Alphas (Ad)Countries Are Investing Heavily Into Securing Energy IndependenceThere's a worldwide "arms race" for countries to secure lithium - the critical metal essential to powering the world's green energy transition. While the U.S. is now investing heavily into lithium production, the North American supply chain has fallen far behind. One company is on a mission to change that and make a previously remote area the next great lithium mining hub.November 3, 2023 | msn.comCompugen receives non-compliance notice from NasdaqNovember 3, 2023 | finance.yahoo.comCompugen Announces Receipt of Nasdaq Minimum Bid Price NotificationOctober 31, 2023 | finance.yahoo.comCompugen to Present New Data at SITC 2023 Suggesting Leading Edge of Anti-IL18 Binding Protein Antibody, COM503, in Treating CancerOctober 24, 2023 | finance.yahoo.comCompugen to Release Third Quarter 2023 Results on Tuesday, November 7, 2023October 3, 2023 | finance.yahoo.comCompugen to Present at Single Cell Genomics 2023 MeetingOctober 2, 2023 | markets.businessinsider.comCompugen Gets Patent In Japan For Combination Of Anti-PVRIG, TIGIT, PD-1 Antibody To Treat CancerOctober 2, 2023 | finance.yahoo.comCompugen Expands Intellectual Property with New Japanese Patent for the Triple Combination of any Anti-PVRIG, TIGIT and PD-1 Antibody for the Treatment of CancerSeptember 27, 2023 | finance.yahoo.comCompugen to Present New Clinical and Pre-Clinical Data in Multiple Presentations at SITC 2023August 31, 2023 | finance.yahoo.comCompugen to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceAugust 23, 2023 | msn.comRoche sends anti-TIGIT developers higher after cancer drug data (update)August 10, 2023 | finance.yahoo.comCompugen Ltd. (NASDAQ:CGEN) Q2 2023 Earnings Call TranscriptAugust 8, 2023 | nl.investing.comCompugen winst hoger dan voorspeld, omzet volgens verwachtingAugust 8, 2023 | markets.businessinsider.com5 Analysts Have This to Say About CompugenAugust 7, 2023 | finance.yahoo.comCompugen Reports Second Quarter 2023 ResultsJuly 24, 2023 | finance.yahoo.comCompugen to Release Second Quarter 2023 Results on Monday, August 7, 2023July 17, 2023 | finance.yahoo.comCompugen Wins on PVRIG European Patent Opposition Pursued by GSK and a Third PartyJuly 15, 2023 | finance.yahoo.comCGEN - Compugen Ltd.July 6, 2023 | msn.comCompugen (CGEN) Price Target Increased by 17.39% to 6.89See More Headlines Receive CGEN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Compugen and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/07/2023Today12/06/2023Fiscal Year End12/31/2023Next Earnings (Estimated)2/26/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CGEN CUSIPN/A CIK1119774 Webwww.cgen.com Phone(723) 765-8585Fax972-3765-8555Employees69Year Founded1993Price Target and Rating Average Stock Price Target$8.33 High Stock Price Target$13.00 Low Stock Price Target$4.00 Potential Upside/Downside+954.9%Consensus RatingModerate Buy Rating Score (0-4)2.60 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($0.37) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-33,690,000.00 Net MarginsN/A Pretax Margin-420.49% Return on Equity-48.16% Return on Assets-39.06% Debt Debt-to-Equity RatioN/A Current Ratio5.81 Quick Ratio6.43 Sales & Book Value Annual Sales$7.50 million Price / Sales9.12 Cash FlowN/A Price / Cash FlowN/A Book Value$0.90 per share Price / Book0.88Miscellaneous Outstanding Shares86,625,000Free Float78,396,000Market Cap$68.43 million OptionableOptionable Beta2.52 Social Links Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesDr. Anat Cohen-Dayag Ph.D. (Age 56)CEO, President & Director Comp: $796.52kDr. Zurit Levine Ph.D. (Age 55)Senior Vice President of Technology Innovation Comp: $345.7kDr. Henry Adewoye M.D. (Age 58)Senior VP & Chief Medical Officer Comp: $605.29kDr. Pierre Ferre Ph.D. (Age 46)Vice President of Preclinical Development Comp: $415.1kMr. Alberto Sessa (Age 61)Chief Financial Officer Dr. Eran Ophir Ph.D. (Age 45)Chief Scientific Officer Ms. Yvonne NaughtonHead of Investor Relations & Corporate CommunicationsMr. Eran Ben DorGeneral Counsel & Corporate SecretaryMs. Dorit Amitay (Age 55)Vice President of Human Resources Dr. Yaron Turpaz M.B.A. (Age 52)Ph.D., Senior VP & Senior Advisor of Data and Informatics Solutions More ExecutivesKey CompetitorsCardiff OncologyNASDAQ:CRDFAVROBIONASDAQ:AVROSolid BiosciencesNASDAQ:SLDBAthira PharmaNASDAQ:ATHACardiol TherapeuticsNASDAQ:CRDLView All CompetitorsInstitutional OwnershipSilverarc Capital Management LLCBought 20,000 shares on 11/13/2023Ownership: 0.404%UBS Group AGBought 27,339 shares on 11/9/2023Ownership: 0.322%Tocqueville Asset Management L.P.Bought 76,500 shares on 11/9/2023Ownership: 0.088%Oppenheimer & Co. Inc.Sold 16,000 shares on 11/8/2023Ownership: 0.042%Kingsview Wealth Management LLCBought 83,991 shares on 11/7/2023Ownership: 0.097%View All Institutional Transactions CGEN Stock Analysis - Frequently Asked Questions Should I buy or sell Compugen stock right now? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Compugen in the last year. There are currently 1 sell rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" CGEN shares. View CGEN analyst ratings or view top-rated stocks. What is Compugen's stock price target for 2024? 5 brokerages have issued 1 year price objectives for Compugen's shares. Their CGEN share price targets range from $4.00 to $13.00. On average, they anticipate the company's stock price to reach $8.33 in the next year. This suggests a possible upside of 954.9% from the stock's current price. View analysts price targets for CGEN or view top-rated stocks among Wall Street analysts. How have CGEN shares performed in 2023? Compugen's stock was trading at $0.7157 at the beginning of 2023. Since then, CGEN stock has increased by 10.4% and is now trading at $0.79. View the best growth stocks for 2023 here. Are investors shorting Compugen? Compugen saw a decline in short interest during the month of November. As of November 15th, there was short interest totaling 1,350,000 shares, a decline of 10.6% from the October 31st total of 1,510,000 shares. Based on an average daily trading volume, of 174,600 shares, the short-interest ratio is currently 7.7 days. Currently, 1.6% of the shares of the company are short sold. View Compugen's Short Interest. When is Compugen's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, February 26th 2024. View our CGEN earnings forecast. How were Compugen's earnings last quarter? Compugen Ltd. (NASDAQ:CGEN) released its earnings results on Tuesday, November, 7th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by $0.02. What is Anat Cohen-Dayag's approval rating as Compugen's CEO? 2 employees have rated Compugen Chief Executive Officer Anat Cohen-Dayag on Glassdoor.com. Anat Cohen-Dayag has an approval rating of 100% among the company's employees. This puts Anat Cohen-Dayag in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Compugen own? Based on aggregate information from My MarketBeat watchlists, some companies that other Compugen investors own include Oramed Pharmaceuticals (ORMP), NVIDIA (NVDA), Advanced Micro Devices (AMD), QUALCOMM (QCOM), AbbVie (ABBV), Inovio Pharmaceuticals (INO), Netflix (NFLX), Gilead Sciences (GILD) and Pfizer (PFE). Who are Compugen's major shareholders? Compugen's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Taylor Frigon Capital Management LLC (2.23%), Silverarc Capital Management LLC (0.40%), UBS Group AG (0.32%), Kingsview Wealth Management LLC (0.10%), Tocqueville Asset Management L.P. (0.09%) and Oppenheimer & Co. Inc. (0.04%). How do I buy shares of Compugen? Shares of CGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:CGEN) was last updated on 12/6/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Compugen Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.